Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Nov;31(11):2063-2067.
doi: 10.1007/s00198-020-05631-6. Epub 2020 Sep 4.

FRAX and ethnicity

J A Kanis  1   2 , C Cooper  3   4 , B Dawson-Hughes  5 , N C Harvey  3   6 , H Johansson  7   8 , M Lorentzon  7   9 , E V McCloskey  8   10 , J-Y Reginster  11   12 , R Rizzoli  13 ; International Osteoporosis Foundation
Affiliations
Editorial

FRAX and ethnicity

J A Kanis et al. Osteoporos Int. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing Interests

JAK, NCH, HJ, ML and EVM are responsible for the creation and maintenance of FRAX but derive no financial benefit.

JAK reports no additional competing interests.

CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB.

BD-H has received grant support from Pfizer and DSM and consulting fees from TTY Biopharma Co, Ltd, Intrinsic Therapeutics and Agnovos.

NCH has received consultancy/lecture fees/honoraria/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Radius Health, Servier, Shire, UCB, Consilient Healthcare and Internis Pharma.

HJ has no conflicts of interest to declare.

ML has received lecture fees from Amgen, Lilly, Meda, Renapharma and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health.

EVM has received consultancy/lecture fees/grant funding/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, Sanofi Aventis, UCB, Viiv, Warner Chilcott, and I3 Innovus.

J-YR has received advisory board or consulting fees from IBSA-Genévrier, Pierre Fabre, Radius Health, TEVA and Mylan; lecture fees from Agnovos, IBSA-Genévrier, Mylan, CNIEL, Dairy Research Council (DRC) and Theramex and institutional grant support from IBSA-Genévrier, Mylan, CNIEL and Radius Health.

RR has received consulting fees or advisory board fees from Radius Health, Labatec, Danone, Nestlé, CNIEL and Sandoz.

Figures

Fig. 1
Fig. 1
10-year probability of hip fracture in men and women age 65 years with a prior fragility fracture in countries where a FRAX model is available. Body mass index set at 25 kg/m2. The diagonal dotted line denotes the line of equality. Hip fracture probability in women ranged from 0.5 to more than 5% - a ten-fold range. Probabilities in women were on average 65% higher than in men.
Fig. 2
Fig. 2
Ethnic specific 10-year probabilities of a major osteoporotic fracture in men and women age 65 years with a prior fragility fracture in the US and South Africa. Body mass index set at 25 kg/m2.
See this image and copyright information in PMC

Comment on

References

    1. Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight — Reconsidering the use of race correction in clinical algorithms. New Engl J Med. 2020;383:874–882. - PubMed
    1. Kolata G. Many medical decision tools disadvantage black patients. [accessed 28 August 2020];New YorkTimes. 2020 New York Times, https://www.nytimes.com/2020/06/17/health/many-medical-decision-tools-di....
    1. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby A. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17:1237–44. - PubMed
    1. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23:2239–56. - PMC - PubMed
    1. Ström O, Lauppe R, Ljunggren Ö, Spångéus A, Ortsäter G, O’Kelly J, Åkesson K. Real-world effectiveness of osteoporosis treatment in the oldest old. Osteoporos Int. 2020;31:1525–1533. - PMC - PubMed